SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer
Open Access
- 1 March 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 12, 2115-2121
- https://doi.org/10.2147/ott.s196725
Abstract
Purpose: The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients. Materials and methods: One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before operation, then KRAS mutation status was analyzed through pathologically confirmed CRC samples. The association between tumor clinical characteristics and PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax), SUVmean, and metabolic tumor volume (MTV), and KRAS mutation status was analyzed using chi-squared tests, Mann–Whitney U tests, and logistic regression analysis. Results: The KRAS mutation type patients exhibited high MTV and high SUVmax using a threshold of 17.8 cm3 and 8.7 respectively and the predictive accuracy was 0.772 and 0.603 respectively. High MTV (P=0.001; 95% CI: 1.119–1.296) and high SUVmax (P=0.048; 95% CI: 0.564–0.985) were independent predictors for KRAS mutation status. Conclusion: MTV and SUVmax were associated with KRAS mutation type in CRC patients. PET/CT metabolic parameters can be used for supplementing KRAS mutation status prediction in CRC patients.Keywords
This publication has 33 references indexed in Scilit:
- Proposal of a New 18F-FDG PET/CT Predictor of Response in Rectal Cancer Treated by Neoadjuvant Chemoradiation Therapy and Comparison With PERCIST CriteriaClinical Nuclear Medicine, 2013
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding MetastasesClinical Cancer Research, 2010
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor CellsScience, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Cetuximab for the Treatment of Colorectal CancerThe New England Journal of Medicine, 2007
- The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinomaGut, 2005
- Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer PatientsJournal of Clinical Oncology, 2005
- Estimates of the worldwide incidence of eighteen major cancers in 1985International Journal of Cancer, 1993